FDA approves Juvisync combination for Type 2 Diabetes and elevated Cholesterol

The FDA has approved MK 0431C or Juvisync (sitagliptin and simvastatin), from Merck, the first single tablet for both Type 2 Diabetes and elevated Cholesterol. Sitagliptin and simvastatin are already approved medications to separately treat these conditions. To meet the different needs of individual patients and to ensure safe and effective use of Juvisync, tablets containing different doses of sitagliptin and simvastatin in fixed-dose combination have been developed. The FDA has approved Juvisync tablets in the following sitagliptin/simvastatin dosages - 100 mg/10 mg, 100 mg/20 mg and 100 mg/40 mg.